phenobarbital

phenobarbital
Name	Phenobarbital
Drug class	Barbiturate
Routes of administration	Oral; intravenous; intramuscular
Legal status	Prescription

phenobarbital is a long-acting barbiturate anticonvulsant and sedative-hypnotic used for seizure control and as an anxiolytic or sedative in some settings. It remains on the World Health Organization WHO Model List of Essential Medicines and is widely used in low-resource settings for neonatal and adult seizure management. Developed in the early 20th century, it has influenced policies, guidelines, and formularies of organizations such as the World Health Organization, American Academy of Neurology, Royal College of Physicians, Centers for Disease Control and Prevention, and national drug agencies.

Medical uses

Phenobarbital is primarily used in the treatment of generalized tonic–clonic seizures, focal seizures, and neonatal seizures where alternatives such as phenytoin or levetiracetam may be unavailable. Clinical protocols from institutions like Johns Hopkins Hospital, Mayo Clinic, Massachusetts General Hospital, and the National Institutes of Health include phenobarbital for status epilepticus when first-line benzodiazepines (e.g., diazepam, lorazepam) fail. It has been employed for sedation in intensive care units of hospitals such as Cleveland Clinic and for alcohol withdrawal management in some community hospital formularies, though contemporary practice often favors agents recommended by the American Society of Addiction Medicine and Substance Abuse and Mental Health Services Administration. Historical use as a hypnotic and anxiolytic declined after the introduction of benzodiazepines like diazepam and alprazolam, and later selective serotonin reuptake inhibitor protocols promoted by psychiatric centers such as McLean Hospital.

Pharmacology

Phenobarbital is a barbiturate that enhances inhibitory neurotransmission by acting as a positive allosteric modulator at the GABAA receptor and, at higher concentrations, directly activating GABAA receptors—mechanisms discussed in literature from research centers including Harvard Medical School, Stanford University, and University College London. It also inhibits excitatory AMPA and kainate receptors and modulates voltage-gated sodium channels, mechanisms described in studies from laboratories at National Institute of Neurological Disorders and Stroke and Salk Institute. The drug induces hepatic cytochrome P450 enzymes, notably CYP2C9 and CYP3A4, a property characterized by investigators at institutions like Dana-Farber Cancer Institute and University of California, San Francisco, leading to altered metabolism of coadministered drugs such as warfarin, oral contraceptives, and antiretrovirals used by programs like World Health Organization HIV treatment initiatives.

Adverse effects

Common adverse effects include sedation, cognitive impairment, ataxia, and mood changes noted in case series from hospitals including Guy's Hospital, Addenbrooke's Hospital, and Royal Infirmary of Edinburgh. Long-term use has been associated with dependence, tolerance, and withdrawal syndromes documented in reports from Royal College of Psychiatrists and American Psychiatric Association. In neonates and pregnant patients, concerns regarding neurodevelopmental outcomes have been raised in cohort studies conducted at Boston Children's Hospital and Great Ormond Street Hospital. Rare but serious reactions include hypersensitivity and severe cutaneous adverse reactions recognized by dermatology centers such as St Vincent's Hospital and hematologic complications reviewed by the British Society for Haematology.

Interactions and contraindications

Because phenobarbital is a potent inducer of hepatic enzymes, it interacts with numerous agents used in specialties represented by centers like Johns Hopkins Medicine, Karolinska Institute, and Imperial College London. Notable interactions include reduced efficacy of hormonal contraceptives observed in reproductive health studies from University of Oxford and altered anticoagulant levels reported by anticoagulation services at University of Toronto. Concomitant use with other central nervous system depressants such as opioids, benzodiazepines, and alcohol increases the risk of respiratory depression, a concern highlighted in guidelines from American College of Emergency Physicians and European Resuscitation Council. Contraindications include porphyria and known hypersensitivity, with management guidance in drug formularies from National Health Service and Food and Drug Administration advisories.

Pharmacokinetics

Phenobarbital is well absorbed orally and achieves peak plasma concentrations described in pharmacology texts from UCSF School of Pharmacy and University of Cambridge. It has a long elimination half-life, influenced by age and hepatic function, with neonates and the elderly demonstrating prolonged clearance reported in pediatrics and geriatric studies from Children's Hospital of Philadelphia and Mayo Clinic. The drug is metabolized hepatically via cytochrome P450 enzymes and excreted renally; therapeutic drug monitoring is recommended by toxicology services at Mount Sinai Hospital and Johns Hopkins Hospital to maintain therapeutic ranges and avoid toxicity.

History and society

Phenobarbital was first synthesized in the early 1910s and introduced into clinical practice in the 1910s–1920s, milestones chronicled in histories from Royal Society of Medicine, Wellcome Trust, and medical museums such as the Hunterian Museum. Its adoption influenced early 20th-century psychiatry and neurology at institutions like Charité – Universitätsmedizin Berlin and Pitié-Salpêtrière Hospital. Over the decades, regulatory decisions by agencies including the Food and Drug Administration, European Medicines Agency, and national health ministries shaped its availability and scheduling. Global public health programs coordinated by the World Health Organization and charitable organizations such as Médecins Sans Frontières have advocated for phenobarbital access in low-resource settings for epilepsy care, while professional societies including the International League Against Epilepsy continue to issue practice parameters addressing its role.

Category:Barbiturates